Satyavrat Shukla
Net worth: 99 149 $ as of 31/08/2026
Net worth: 99 149 $ as of 31/08/2026
Satyavrat Shukla worked at Cornerstone Research, Inc. as Principal from 2003 to 2012.
Then worked at Vertex Pharmaceuticals, Inc. as Vice President & Global Head-Corporate Finance from 2012 to 2019.
Worked at Alaunos Therapeutics, Inc. as Chief Financial Officer & Executive Vice President from 2019 to 2020.
Worked at Spero Therapeutics, Inc. as Director in 2025.
Education includes an undergraduate degree from Harvard University in 1993 and an MBA from Yale University in 1999.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/04/2026 | 81,270 ( 0.14% ) | 99 149 $ | 31/08/2026 |
| Companies | Position | End |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Chief Executive Officer | 10/01/2025 |
| ALAUNOS THERAPEUTICS, INC. | Director of Finance/CFO | 31/12/2020 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/07/2019 |
Cornerstone Research, Inc.
Cornerstone Research, Inc. Miscellaneous Commercial ServicesCommercial Services Provides testimony, economic and financial analysis to attorneys | Corporate Officer/Principal | 01/01/2012 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornerstone Research, Inc.
Cornerstone Research, Inc. Miscellaneous Commercial ServicesCommercial Services Provides testimony, economic and financial analysis to attorneys | Commercial Services |
Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Spero Therapeutics, Inc.
Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
Select your edition
All financial news and data tailored to specific country editions